Journey Medical Corp (DERM): Revenue
$61.24M
Year ended 2025-12-31
$66.85M
Trailing 12 months to 2026-06-30
-4.8%
3-year compound annual growth
+6.6%
5-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $61.24M | +11.1% | 2026-03-26, From 2025-01-01 |
| 2024-12-31 | $55.13M | -7.6% | 2026-03-26, From 2024-01-01 |
| 2023-12-31 | $59.66M | -16.0% | 2025-03-27, From 2023-01-01 |
| 2022-12-31 | $71.00M | +12.5% | 2024-03-29, From 2022-01-01 |
| 2021-12-31 | $63.13M | +41.8% | 2023-03-31, From 2021-01-01 |
| 2020-12-31 | $44.53M | n/a | 2022-03-28, From 2020-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Journey Medical Corp (DERM) | 2025-12-31 | $61.24M | +11.1% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $62.38M | +48.3% |
| Nuvation Bio Inc. (NUVB) | 2025-12-31 | $62.90M | +699.0% |
| Fortress Biotech, Inc. (FBIO) | 2025-12-31 | $63.26M | +9.7% |
| Aytu Biopharma, Inc (AYTU) | 2026-06-30 | $57.57M | -13.3% |
| Enanta Pharmaceuticals Inc (ENTA) | 2025-09-30 | $65.32M | -3.4% |
| Spero Therapeutics, Inc. (SPRO) | 2025-12-31 | $66.80M | +39.2% |
| Kura Oncology, Inc. (KURA) | 2025-12-31 | $67.48M | +25.2% |
| Nektar Therapeutics (NKTR) | 2025-12-31 | $55.23M | -43.9% |
Compare DERM, TNGX, NUVB, FBIO side by side · Screen every company in Pharmaceutical Preparations ↗